Humacyte, Inc.

For the period ended Sep 30, 2026. Filed Nov 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 10, 2026

HUMA$0.59+29.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands except for share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Revenue:
Product revenue, net	$1,023	$703	$1,922	$950
Contract revenue	5	50	7	621
Total revenue	1,028	753	1,929	1,571
Operating expenses:
Cost of goods sold	1,429	260	4,698	620
Research and development	14,104	17,273	51,710	54,697
General and administrative	9,014	7,610	24,971	23,555
Total operating expenses	24,547	25,143	81,379	78,872
Loss from operations	(23,519)	(24,390)	(79,450)	(77,301)
Other income (expense), net:
Interest income	601	590	1,319	2,084
Interest expense	(2,370)	(2,612)	(6,962)	(8,157)
Change in fair value of Contingent Earnout Liability	3,387	4,893	5,401	49,154
Change in fair value of derivatives	6,363	4,009	9,733	18,191
Total other income, net	7,981	6,880	9,491	61,272
Net loss and comprehensive loss	$(15,538)	$(17,510)	$(69,959)	$(16,029)
Net loss per share attributable to common stockholders, basic and diluted	$(0.06)	$(0.11)	$(0.30)	$(0.11)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted	277,798,105	158,313,290	236,901,920	148,514,044

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.